Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
83 hedge funds and large institutions have $86.9M invested in Regulus Therapeutics in 2016 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 21 increasing their positions, 26 reducing their positions, and 12 closing their positions.
2,782% more call options, than puts
Call options by funds: $9.71M | Put options by funds: $337K
10% more capital invested
Capital invested by funds: $78.9M → $86.9M (+$8.08M)
0% more funds holding
Funds holding: 83 → 83 (0)
0% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 12
19% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$2.21M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$877K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$875K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$410K |
| 5 |
HCM
Highbridge Capital Management
New York
|
+$357K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$1.83M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.39M |
| 3 |
Goldman Sachs
New York
|
-$1.3M |
| 4 |
CPIM
Columbia Partners Investment Management
Alexandria,
Virginia
|
-$1.11M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$814K |
RGLS Hedge Fund Activity: Q3 2016 in Review
83 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q3 2016, worth a combined $86.9M — up 10% from $78.9M a quarter earlier.
Fund positioning in RGLS was balanced in Q3 2016: 12 funds opened new positions, 12 closed out, 21 added to existing stakes and 26 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $2.21M. The largest seller was Numeric Investors, cutting an estimated $1.83M.
- 83 institutional investors held Regulus Therapeutics (RGLS) as of Q3 2016, unchanged from Q2 2016.
- Funds reported $86.9M of Regulus Therapeutics stock for Q3 2016, up 10% quarter-over-quarter.
- 12 funds opened new Regulus Therapeutics positions in Q3 2016 and 12 closed out, a net change of 0 holders.
- The largest Regulus Therapeutics buyer in Q3 2016 was Renaissance Technologies, an estimated $2.21M added.
- The largest Regulus Therapeutics seller in Q3 2016 was Numeric Investors, an estimated $1.83M sold.
Based on aggregated 13F filings for Q3 2016.